Liposomal Finasteride Topical Formulation for Scalp Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for male pattern baldness, such as oral finasteride, are associated with significant systemic side effects due to widespread serum uptake of the active ingredient, leading to poor patient compliance and potential long-term adverse effects like erectile dysfunction.
Innovation Solution
Development of a liposomal topical formulation that utilizes a depot effect to sustainably release 5-α-reductase inhibitors, such as finasteride, directly into the scalp, minimizing systemic absorption and reducing serum DHT suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral finasteride is used to treat male pattern baldness, then hair loss is effectively arrested and new hair growth is promoted, but systemic side effects occur including low libido, erectile dysfunction, and decreased arousal
Solution Approach 1:
The invention divides the delivery system into distinct components: liposomes containing finasteride are incorporated into a hydrogel matrix. This segmentation allows the drug to be delivered in a controlled, localized manner rather than systemically, achieving therapeutic effect at the scalp while minimizing systemic absorption and side effects
Solution Approach 2:
The topical formulation delivers finasteride locally to the scalp with high concentration at the application site. The hydrogel matrix provides sustained local release, creating a high drug concentration where it is needed (scalp) while maintaining low systemic levels, thus achieving effective hair loss treatment without the systemic side effects associated with oral administration
2Reliability
If topical formulations with high finasteride concentration are used, then therapeutic efficacy is improved, but serum DHT suppression increases leading to adverse effects
Solution Approach 1:
The liposomal encapsulation prepares finasteride for controlled release before application. The liposomes are pre-formed and incorporated into the hydrogel matrix, which then provides sustained release over time. This preliminary preparation ensures that the drug is delivered gradually at therapeutic levels without causing excessive serum DHT suppression
Solution Approach 2:
The hydrogel matrix acts as an intermediary between the liposomal finasteride and the scalp tissue. It controls the release kinetics, providing sustained delivery that maintains therapeutic efficacy while preventing excessive absorption into systemic circulation. The matrix mediates the balance between local therapeutic concentration and systemic exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical formulation achieves localized and sustained delivery of finasteride, significantly reducing systemic exposure and associated side effects, while maintaining therapeutic efficacy in treating male pattern baldness.
Implementation Method 1
a liposomal topical formulation comprising: a plurality of liposomes; one or more active pharmaceutical ingredients (API); and an aqueous gel matrix in which the plurality of liposomes are dispersed
Implementation Method 2
The topical formulations described herein provide a 'depot' effect by which the 5-α-reductase inhibitors are largely retained in the outer layers of the skin, e.g., epidermis and part of the dermis
Data Source
AI summary
The present invention provides a liposomal topical formulation or a liposomal topical formulation base having barrier-forming siliconic components, methods for making the same, and methods for using the same in the treatment of dermatological diseases and conditions, including male pattern baldness.